Abstract
In this study we set out to investigate whether anti PDL1 or PD-1 treatment targeting the immune system could be used against multiple myeloma. DCs are important in regulating T cell responses against tumors. We therefore determined PDL1 and PDL2 expression on DC populations in bone marrow of patients with plasma cell disorders using multicolour Flow Cytometry. We specifically looked at CD141+ and CD141- myeloid and CD303+ plasmacytoid DC. The majority of plasma cells (PC) and DC subpopulations expressed PDL1, but the proportion of positive PDL1+ cells varied among patients. A correlation between the proportion of PDL1+ PC and CD141+ mDC was found, suggesting both cell types could down-regulate the anti-tumor T cell response.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents / therapeutic use
-
B7-H1 Antigen / antagonists & inhibitors
-
B7-H1 Antigen / metabolism*
-
Bone Marrow Cells / metabolism*
-
Dendritic Cells / metabolism*
-
Flow Cytometry
-
Humans
-
Multiple Myeloma / drug therapy
-
Multiple Myeloma / metabolism*
-
Plasma Cells / metabolism*
Substances
-
Antineoplastic Agents
-
B7-H1 Antigen
-
CD274 protein, human
Grants and funding
The work was supported by K.G. Jebsen Foundation for Medical Research, The Cancer Society of Norway, The Regional Health Research Foundation, and The Research Council of Norway (Grant no. 223255/F50). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript